Registration Dossier

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
other: Weight of evidence
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)

Data source

Reference
Reference Type:
other: Weight of evidence
Title:
Toxicokinetics
Author:
Sustainability Support Services (Europe) AB
Year:
2012
Bibliographic source:
Based on the weight of evidence of dermal toxicology

Materials and methods

Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Based on the observation of dermal toxicology and other relevant paraments
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate
EC Number:
226-501-6
EC Name:
3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate
Cas Number:
5413-60-5
Molecular formula:
C12H16O2
IUPAC Name:
3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate

Test animals

Species:
other: unspecified
Strain:
not specified
Sex:
not specified

Administration / exposure

Route of administration:
other: estimation
Vehicle:
unchanged (no vehicle)

Results and discussion

Preliminary studies:
Based on the results of dermal toxicokinetics it can be stated that the substance will have low absorption capability similar to as shown in dermal absorption, according to which the Danish (Q)SAR dermal absorption of 3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate is 0.00300 mg/cm2/event. This value indicates low dermal absorption.

Toxicokinetic / pharmacokinetic studies

Details on absorption:
The absorption capacity of 3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate is low, which is also supported by the fact that the bioaccumulation factor for the substance is much lower and so even after the exposure the absorption capability will be less in this case.
Details on distribution in tissues:
In case the substance,3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate, is absorbed (though in small quantity) it will not be accumulated in the body. This is supported by the fact that the substance have not only low BCF value but also have a moderate level of Kow which will support the reasoning that though the substance will enter the body but will get distributed through the lipid in the body.
Details on excretion:
Further to this distribution after the absorption process, the excretion process through urine would be faster as the molecular weight of the substance, 3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate, is > 300 and this is a favourable value for excretion via the urine route.

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): no bioaccumulation potential based on study results
Executive summary:

In case the substance,3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-6-yl acetate, is absorbed (though in small quantity) it will not be accumulated in the body. This is supported by the fact that the substance have not only low BCF value but alos have a moderate level of Kow which will support the reasoning that though the substance will enter the body but will get distributed through the lipid in the body.

Categories Display